Charles River Laboratories International In

Find Ratings Reports
CRL : NYSE : Health Care
$87.79 up 1.44 | 1.67%
Today's Range: 86.07 - 87.98
Avg. Daily Volume: 378,200
07/26/16 - 4:02 PM ET

Financial Analysis


CHARLES RIVER LABS INTL INC's gross profit margin for the first quarter of its fiscal year 2016 has increased when compared to the same period a year ago. The company has grown its sales and net income during the past quarter when compared with the same quarter a year ago, and although its growth in net income has outpaced the industry average, its revenue growth has not. CHARLES RIVER LABS INTL INC has average liquidity. Currently, the Quick Ratio is 1.50 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has increased by 17.49% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)354.87320.41
EBITDA ($mil)82.866.17
EBIT ($mil)58.1543.8
Net Income ($mil)37.1431.54


Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)176.38168.68
Total Assets ($mil)2103.721847.23
Total Debt ($mil)861.86786.41
Equity ($mil)779.82663.71


Profitability Q1 FY16 Q1 FY15
Gross Profit Margin44.9542.26
EBITDA Margin23.3320.65
Operating Margin16.3813.67
Sales Turnover0.660.71
Return on Assets7.366.82
Return on Equity19.9819.2
Debt Q1 FY16 Q1 FY15
Current Ratio2.062.27
Debt/Capital0.530.54
Interest Expense4.213.02
Interest Coverage13.8114.48


Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)47.1147.36
Div / share0.00.0
EPS0.780.66
Book value / share16.5514.02
Institutional Own % n/a n/a
Avg Daily Volume375201.0549987.0

Valuation


BUY. CHARLES RIVER LABS INTL INC's P/E ratio indicates a discount compared to an average of 34.13 for the Life Sciences Tools & Services industry and a value on par with the S&P 500 average of 25.05. For additional comparison, its price-to-book ratio of 5.20 indicates a significant premium versus the S&P 500 average of 2.81 and a discount versus the industry average of 5.55. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, CHARLES RIVER LABS INTL INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
CRL 26.22 Peers 34.13   CRL 12.82 Peers 22.48

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

CRL is trading at a discount to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

CRL is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
CRL 17.17 Peers 25.21   CRL 0.67 Peers 1.53

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

CRL is trading at a discount to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

CRL trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
CRL 5.20 Peers 5.55   CRL 22.38 Peers 34.26

Average. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

CRL is trading at a valuation on par with its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, CRL is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
CRL 2.90 Peers 22.92   CRL 5.99 Peers 6.67

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

CRL is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

CRL trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades